Grail Shares Drop After Mixed Results from Galleri Test Trial Presented at ASCO
Grail's stock fell 12.10% following mixed results from its multi-cancer early detection test trial with the NHS, presented at the American Society of Clinical Oncology (ASCO) meeting. The data failed to show a statistically significant reduction in later-stage cancers but showed some positive outcomes for specific cancer types.
Tickers: $GRAL
Topics: ASCO presentation cancer detection Galleri test Grail